Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclovirobuxine D is a **steroidal alkaloid** extracted from *Buxus microphylla* and *Buxus sinica*, traditional Chinese medicinal plants[1][3][6]. It is historically used as a cardiovascular drug in China to treat coronary heart disease, angina, arrhythmias, and heart failure[6]. Cyclovirobuxine D demonstrates pronounced **analgesic** effects in inflammatory and neuropathic pain models in mice, primarily by inhibiting **voltage-gated calcium channels (Ca_v_3.2 > Ca_v_2.2)**[1]. It also has emerging **anticancer properties**, inducing apoptosis and mitochondrial dysfunction in various cancer cell lines—mechanistically acting via pathways such as **CTHRC1-AKT/ERK-Snail**, **EGFR-FAK-AKT/ERK1/2-Slug**, and **Akt/mTOR**, leading to cell death by apoptosis or autophagy[3][7][9]. Its mechanism in cardioprotection may involve antioxidant and myocardial protective effects[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclovirobuxine D.